NASDAQ:SHPH Shuttle Pharmaceuticals (SHPH) Stock Price, News & Analysis $0.21 -0.02 (-10.30%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Shuttle Pharmaceuticals Stock (NASDAQ:SHPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SHPH alerts:Sign Up Key Stats Today's Range$0.21▼$0.2350-Day Range$0.21▼$0.4852-Week Range$0.20▼$4.71Volume3.34 million shsAverage Volume1.49 million shsMarket Capitalization$1.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewShuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.Read More… Shuttle Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreSHPH MarketRank™: Shuttle Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Shuttle Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Shuttle Pharmaceuticals is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shuttle Pharmaceuticals is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShuttle Pharmaceuticals has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.28% of the float of Shuttle Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverShuttle Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shuttle Pharmaceuticals has recently increased by 961.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldShuttle Pharmaceuticals does not currently pay a dividend.Dividend GrowthShuttle Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted21.28% of the float of Shuttle Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverShuttle Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shuttle Pharmaceuticals has recently increased by 961.04%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News Sentiment0.99 News SentimentShuttle Pharmaceuticals has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Shuttle Pharmaceuticals this week, compared to 1 article on an average week.Search Interest5 people have searched for SHPH on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows8 people have added Shuttle Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shuttle Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.60% of the stock of Shuttle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.58% of the stock of Shuttle Pharmaceuticals is held by institutions.Read more about Shuttle Pharmaceuticals' insider trading history. Receive SHPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shuttle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SHPH Stock News HeadlinesShuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical TrialMay 8, 2025 | globenewswire.comShuttle Pharmaceuticals to Present Phase 2 Trial Update at Planet MicroCap Showcase: VEGAS 2025April 24, 2025 | nasdaq.comGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.May 13, 2025 | Premier Gold Co (Ad)Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 21, 2025 | globenewswire.comShuttle Pharmaceuticals files provisional patent application with USPTOApril 12, 2025 | markets.businessinsider.comShuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApril 10, 2025 | globenewswire.comShuttle Pharmaceuticals Appoints New Interim CEO and CSOMarch 31, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc. Closes $5.75 Million Public Offering to Fund Phase II Clinical TrialMarch 13, 2025 | quiverquant.comSee More Headlines SHPH Stock Analysis - Frequently Asked Questions How have SHPH shares performed this year? Shuttle Pharmaceuticals' stock was trading at $0.8590 at the beginning of 2025. Since then, SHPH stock has decreased by 75.8% and is now trading at $0.2081. View the best growth stocks for 2025 here. How were Shuttle Pharmaceuticals' earnings last quarter? Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced its earnings results on Thursday, May, 8th. The company reported ($0.30) earnings per share for the quarter. When did Shuttle Pharmaceuticals IPO? Shuttle Pharmaceuticals (SHPH) raised $10 million in an IPO on Wednesday, August 31st 2022. The company issued 1,225,888 shares at $8.13 per share. How do I buy shares of Shuttle Pharmaceuticals? Shares of SHPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Shuttle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shuttle Pharmaceuticals investors own include Mullen Automotive (MULN), MSP Recovery (LIFW), MSP Recovery (LIFW), NIO (NIO), Tesla (TSLA), Broadcom (AVGO) and AMTD Digital (HKD). Company Calendar Last Earnings5/08/2025Today5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SHPH CIK1757499 Webwww.shuttlepharma.com Phone240-403-4212FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-583.02% Return on Assets-258.92% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book0.10Miscellaneous Outstanding Shares6,258,000Free Float2,463,000Market Cap$1.30 million OptionableNot Optionable Beta-0.93 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:SHPH) was last updated on 5/13/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shuttle Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shuttle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.